BC Week In Review | Mar 29, 2019
Clinical News

Velicept's overactive bladder therapy meets in Phase IIb

Velicept said solabegron met the primary endpoint in the Phase IIb VEL-2002 trial to treat overactive bladder. The company plans to start a Phase III program of the next-generation adrenergic receptor β 3 (ADRB3) agonist...
BC Extra | Mar 19, 2019
Clinical News

Urovant shares slide on vibegron overactive bladder data

Despite hitting the co-primary endpoints for an indication in need of treatment options, Urovant's overactive bladder therapy vibegron underwhelmed investors with its latest data on Tuesday by performing only marginally better than the generic comparator...
BC Extra | May 28, 2015
Company News

Astellas adds muscle disease, ophthalmology TAs

Astellas Pharma Inc. (Tokyo:4503) released a new three-year strategic plan that adds muscle diseases and ophthalmology as therapeutic areas. The company's innovative medicines strategy for FY15-17 also will include development of next-generation vaccines and cell...
BC Week In Review | Sep 15, 2014
Clinical News

Betmiga mirabegron regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that Betmiga mirabegron from Astellas provides no additional benefit over appropriate comparators defined by Germany's Federal Joint Committee (G-BA) to...
BC Innovations | Jul 24, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Adrenergic receptor b3 (ADRB3) Studies in patient samples and mice suggest protecting nestin-positive bone marrow mesenchymal stem cells (MSCs) or their neural regulation could...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BC Week In Review | Jul 1, 2013
Clinical News

Betmiga mirabegron regulatory update

The U.K.'s NICE issued final guidance recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are not suitable. The guidance is in line with...
BC Week In Review | May 20, 2013
Clinical News

Betmiga mirabegron regulatory update

The U.K.'s NICE issued final appraisal determination (FAD) recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are not suitable. The committee concluded that...
BC Week In Review | Apr 15, 2013
Company News

Astellas sales and marketing update

Astellas' Astellas Pharma Canada Inc. subsidiary launched Myrbetriq mirabegron in Canada to treat overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency. The wholesale acquisition cost is C$1.74 ($1.71) per pill. The...
BC Week In Review | Mar 18, 2013
Clinical News

Myrbetriq mirabegron regulatory update

Astellas' Astellas Pharma Canada Inc. subsidiary said Health Canada approved Myrbetriq mirabegron to treat overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency. The subsidiary said it plans to launch the product...
Items per page:
1 - 10 of 40